-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Chengdu Baiyu Pharmaceutical entered the administrative approval stage with its generic apixaban tablets, which were reported for production in Category 4.
It is expected to become the second antithrombotic drug approved by the company
.
According to data from Minet.
com, the global sales of apixaban in 2021 will reach a new high, exceeding US$10 billion
.
It is expected to become the second antithrombotic drug approved by the company
.
According to data from Minet.
com, the global sales of apixaban in 2021 will reach a new high, exceeding US$10 billion
.
Source: State Food and Drug Administration official website
Apixaban is a potent, oral, reversible, direct and highly selective factor Xa active site inhibitor jointly developed by Pfizer and Bristol-Myers Squibb.
Prevention of venous thromboembolic events in adult patients undergoing elective joint or knee replacement surgery
.
Prevention of venous thromboembolic events in adult patients undergoing elective joint or knee replacement surgery
.
Apixaban was first approved by the EMA in May 2011, approved by the FDA and PMDA in December 2012, and approved to enter the domestic market in January 2013.
In 2021, global sales will hit a new high, exceeding US$10 billion
.
In 2021, global sales will hit a new high, exceeding US$10 billion
.
Global sales of apixaban
Image source: Sales database of multinational listed companies on Minet.
com
com
At present, there are more than 20 domestic enterprises that have the approval for the production of apixaban tablets, and the sales scale of this product in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will break through in 2020.
100 million yuan, a year-on-year increase of more than 100%
.
Affected by centralized procurement, the growth rate will decline in the first half of 2021
.
100 million yuan, a year-on-year increase of more than 100%
.
Affected by centralized procurement, the growth rate will decline in the first half of 2021
.
Review of Apixaban Tablets
Source: Minet Consistency Evaluation Database
According to the data of Minet.
com, more than 20 companies have passed or deemed to have passed the consistency evaluation of apixaban tablets, including well-known companies such as Qilu, Yangzijiang, CSPC, Kelun, and Hansoh
.
com, more than 20 companies have passed or deemed to have passed the consistency evaluation of apixaban tablets, including well-known companies such as Qilu, Yangzijiang, CSPC, Kelun, and Hansoh
.
Some antithrombotic drugs deployed by Chengdu Baiyu Pharmaceutical Co.
, Ltd.
, Ltd.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In terms of antithrombotic drugs, Chengdu Baiyu Pharmaceutical submitted 3 generic drug marketing applications under new classifications, among which rivaroxaban tablets have been approved for production and are deemed to have been reviewed, and apixaban tablets are expected to become the company's second approved drug Reviewed antithrombotic drugs
.
Vorapaxa is a new cardiovascular drug approved by the FDA in 2014.
The original research has not yet been approved for import, and no generic drugs have been approved in China
.
.
Vorapaxa is a new cardiovascular drug approved by the FDA in 2014.
The original research has not yet been approved for import, and no generic drugs have been approved in China
.
A few days ago, Chengdu Baiyu Pharmaceutical entered the administrative approval stage with its generic apixaban tablets, which were reported for production in Category 4.
It is expected to become the second antithrombotic drug approved by the company
.
According to data from Minet.
com, the global sales of apixaban in 2021 will reach a new high, exceeding US$10 billion
.
It is expected to become the second antithrombotic drug approved by the company
.
According to data from Minet.
com, the global sales of apixaban in 2021 will reach a new high, exceeding US$10 billion
.
Source: State Food and Drug Administration official website
Apixaban is a potent, oral, reversible, direct and highly selective factor Xa active site inhibitor jointly developed by Pfizer and Bristol-Myers Squibb.
Prevention of venous thromboembolic events in adult patients undergoing elective joint or knee replacement surgery
.
Prevention of venous thromboembolic events in adult patients undergoing elective joint or knee replacement surgery
.
Apixaban was first approved by the EMA in May 2011, approved by the FDA and PMDA in December 2012, and approved to enter the domestic market in January 2013.
In 2021, global sales will hit a new high, exceeding US$10 billion
.
In 2021, global sales will hit a new high, exceeding US$10 billion
.
Global sales of apixaban
Image source: Sales database of multinational listed companies on Minet.
com
com
At present, there are more than 20 domestic enterprises that have the approval for the production of apixaban tablets, and the sales scale of this product in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will break through in 2020.
100 million yuan, a year-on-year increase of more than 100%
.
Affected by centralized procurement, the growth rate will decline in the first half of 2021
.
100 million yuan, a year-on-year increase of more than 100%
.
Affected by centralized procurement, the growth rate will decline in the first half of 2021
.
Review of Apixaban Tablets
Source: Minet Consistency Evaluation Database
According to the data of Minet.
com, more than 20 companies have passed or deemed to have passed the consistency evaluation of apixaban tablets, including well-known companies such as Qilu, Yangzijiang, CSPC, Kelun, and Hansoh
.
com, more than 20 companies have passed or deemed to have passed the consistency evaluation of apixaban tablets, including well-known companies such as Qilu, Yangzijiang, CSPC, Kelun, and Hansoh
.
Some antithrombotic drugs deployed by Chengdu Baiyu Pharmaceutical Co.
, Ltd.
, Ltd.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In terms of antithrombotic drugs, Chengdu Baiyu Pharmaceutical submitted 3 generic drug marketing applications under new classifications, among which rivaroxaban tablets have been approved for production and are deemed to have been reviewed, and apixaban tablets are expected to become the company's second approved drug Reviewed antithrombotic drugs
.
Vorapaxa is a new cardiovascular drug approved by the FDA in 2014.
The original research has not yet been approved for import, and no generic drugs have been approved in China
.
.
Vorapaxa is a new cardiovascular drug approved by the FDA in 2014.
The original research has not yet been approved for import, and no generic drugs have been approved in China
.
A few days ago, Chengdu Baiyu Pharmaceutical entered the administrative approval stage with its generic apixaban tablets, which were reported for production in Category 4.
It is expected to become the second antithrombotic drug approved by the company
.
According to data from Minet.
com, the global sales of apixaban in 2021 will reach a new high, exceeding US$10 billion
.
It is expected to become the second antithrombotic drug approved by the company
.
According to data from Minet.
com, the global sales of apixaban in 2021 will reach a new high, exceeding US$10 billion
.
Source: State Food and Drug Administration official website
Apixaban is a potent, oral, reversible, direct and highly selective factor Xa active site inhibitor jointly developed by Pfizer and Bristol-Myers Squibb.
Prevention of venous thromboembolic events in adult patients undergoing elective joint or knee replacement surgery
.
Prevention of venous thromboembolic events in adult patients undergoing elective joint or knee replacement surgery
.
Apixaban was first approved by the EMA in May 2011, approved by the FDA and PMDA in December 2012, and approved to enter the domestic market in January 2013.
In 2021, global sales will hit a new high, exceeding US$10 billion
.
In 2021, global sales will hit a new high, exceeding US$10 billion
.
Global sales of apixaban
Image source: Sales database of multinational listed companies on Minet.
com
com
At present, there are more than 20 domestic enterprises that have the approval for the production of apixaban tablets, and the sales scale of this product in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will break through in 2020.
100 million yuan, a year-on-year increase of more than 100%
.
Affected by centralized procurement, the growth rate will decline in the first half of 2021
.
Enterprise Enterprise Enterprise Hospital Hospital Hospital100 million yuan, a year-on-year increase of more than 100%
.
Affected by centralized procurement, the growth rate will decline in the first half of 2021
.
Review of Apixaban Tablets
Source: Minet Consistency Evaluation Database
According to the data of Minet.
com, more than 20 companies have passed or deemed to have passed the consistency evaluation of apixaban tablets, including well-known companies such as Qilu, Yangzijiang, CSPC, Kelun, and Hansoh
.
com, more than 20 companies have passed or deemed to have passed the consistency evaluation of apixaban tablets, including well-known companies such as Qilu, Yangzijiang, CSPC, Kelun, and Hansoh
.
Some antithrombotic drugs deployed by Chengdu Baiyu Pharmaceutical Co.
, Ltd.
, Ltd.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In terms of antithrombotic drugs, Chengdu Baiyu Pharmaceutical submitted 3 generic drug marketing applications under new classifications, among which rivaroxaban tablets have been approved for production and are deemed to have been reviewed, and apixaban tablets are expected to become the company's second approved drug Reviewed antithrombotic drugs
.
Vorapaxa is a new cardiovascular drug approved by the FDA in 2014.
The original research has not yet been approved for import, and no generic drugs have been approved in China
.
.
Vorapaxa is a new cardiovascular drug approved by the FDA in 2014.
The original research has not yet been approved for import, and no generic drugs have been approved in China
.
